Table 4 Avenio ctDNA kit sensitivity for Fusions and amplifications

Expanded

HD786

5% structural ref. std.

Reference Std

40

AMPLIFICATION

MET

N/A

AMP

AMP

100%

FUSION

ROS1

SLC34A2/ROS1

5.6%

SLC34A2 ROS1

FUSION

RET

CCDC6/RET

5.6%

RET CCDC6

“HD787”

2.5% structural ref. std.

Reference Std

40

AMPLIFICATION

MET

N/A

AMP

AMP

100%

FUSION

ROS1

SLC34A2/ROS1

2.8%

SLC34A2 ROS1

FUSION

RET

CCDC6/RET

2.8%

RET CCDC6

“HD788”

1% structural ref. std.

Reference Std

40

AMPLIFICATION

MET

N/A

AMP

AMP

67%

FUSION

ROS1

SLC34A2/ROS1

1.1%

SLC34A2-ROS1

FUSION

RET

CCDC6/RET

1.1%

ND

Surveillance

0710–140

Seracare 1% ref. std

Reference Std

20

FUSION

ALK

TPR-ALK

1.00%

TPR-ALK

100%

FUSION

RET

NCOA4-RET

1.00%

NCOA4-RET

0710–141

Seracare 0.5% ref. std

Reference Std

20

FUSION

ALK

TPR-ALK

0.50%

ND

50%

FUSION

RET

NCOA4-RET

0.50%

NCOA4-RET

Targeted

0710–0529

Seracare 2.5% ref. std

Reference Std

20

FUSION

ALK

EML4-ALKv1

2.5%

ALK;EML4

80%

FUSION

RET

NCOA4-RET

2.5%

RET;NCOA4

FUSION

ROS1

CD74-ROS1**

2.5%

ND**

AMPLIFICATION

ERBB2

ERBB2

2.5%

AMP

AMPLIFICATION

MET

MET

2.5%

AMP

0710–0531

Seracare 0.5% ref. std

Reference Std

20

FUSION

ALK

EML4-ALKv1

0.5%

ND

0%

FUSION

RET

NCOA4-RET

0.5%

ND

FUSION

ROS1

CD74-ROS1

0.5%

ND

AMPLIFICATION

ERBB2

ERBB2

0.5%

ND

AMPLIFICATION

MET

MET

0.5%

ND

0710–0529

Seracare 2.5% ref. std

Reference Std

10

FUSION

ALK

EML4-ALKv1

2.5%

ALK;EML4

60%

FUSION

RET

NCOA4-RET

2.5%

RET;NCOA4

FUSION

ROS1

CD74-ROS1**

2.5%

ND**

AMPLIFICATION

ERBB2

ERBB2

2.5%

ND

AMPLIFICATION

MET

MET

2.5%

AMP

0710–0531

Seracare 0.5% ref. std

Reference Std

10

FUSION

ALK

EML4-ALKv1

0.5%

ND

0%

FUSION

RET

NCOA4-RET

0.5%

ND

FUSION

ROS1

CD74-ROS1

0.5%

ND

AMPLIFICATION

ERBB2

ERBB2

0.5%

ND

AMPLIFICATION

MET

MET

0.5%

ND